Methods for treatment of parkinson's disease
AssigneeNewron Pharmaceuticals S.p.A.
InventorsRuggero Fariello, Carlo Cattaneo, Patricia Salvati, Luca Benatti
Life of this patent
Estimating the term…
Abstract
New uses of safinamide, safinamide derivatives and MAO-B inhibitors in novel types of treatment for Parkinson's Disease are described. More specifically, the invention relates to methods for treating Parkinson's Disease through the administration of safinamide, a safinamide derivative, or a MAO-B inhibitor, in combination with other Parkinson's Disease agents or treatments, such as levodopa/PDI or dopamine agonists.
Claims10
In a method of treating idiopathic Parkinson's disease in a patient receiving a stable dose of levodopa, the improvement comprising:
- concurrently administering safinamide, or a pharmaceutically acceptable salt thereof, on an oral dosage schedule of about 0.5 mg/kg/day to about 5 mg/kg/day,
- while maintaining the patient on a stable dose of levodopa.
A method of treating idiopathic Parkinson's Disease, comprising:
- administering a therapeutically effective stable dose of levodopa;
- and
- concurrently administering safinamide, or a pharmaceutically acceptable salt thereof, on an oral dosage schedule of about 0.5 mg/kg/day to about 5 mg/kg/day.
Dependencies are inferred from the claim text.